{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T10:34:44Z","timestamp":1782902084269,"version":"3.54.5"},"reference-count":10,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2017,3,30]]},"abstract":"<jats:p>Propafenone is a Vaughan Williams class 1c antiarrhythmic medication widely used for treatment of arrhythmias. Although the long-term safety of propafenone use has not been established, it is commonly used for treatment of atrial fibrillation in patients with no structural heart disease. Propafenone is well known as<jats:italic>pill-in-the-pocket<\/jats:italic>treatment for its effect in terminating paroxysmal episodes of atrial fibrillation. Herein, we discuss an unusual adverse reaction to propafenone in a patient who presented with symptomatic bradycardia and hypotension. The aim of this article is to increase physician awareness for propafenone toxicity and its management, with a focused literature review on propafenone pharmacotherapy.<\/jats:p>","DOI":"10.1136\/bcr-2017-219270","type":"journal-article","created":{"date-parts":[[2017,4,26]],"date-time":"2017-04-26T12:15:32Z","timestamp":1493208932000},"page":"bcr-2017-219270","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["Revisiting propafenone toxicity"],"prefix":"10.1136","volume":"2017","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9143-5269","authenticated-orcid":false,"given":"Ali A","family":"Alsaad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahaira","family":"Ortiz Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher O","family":"Austin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Kusumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,4,26]]},"reference":[{"key":"2025042705582768000_2017.apr26_1.bcr-2017-219270.1","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/j.1476-5381.1988.tb11737.x","article-title":"Electrophysiological mechanism for the antiarrhythmic action of propafenone: a comparison with mexiletine","volume":"95","author":"Amerini","year":"1988","journal-title":"Br J Pharmacol"},{"key":"2025042705582768000_2017.apr26_1.bcr-2017-219270.2","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1365-2796.1995.tb01225.x","article-title":"Propafenone in a usual dose produces severe side-effects: the impact of genetically determined metabolic status on drug therapy","volume":"238","author":"M\u00f6rike","year":"1995","journal-title":"J Intern Med"},{"key":"2025042705582768000_2017.apr26_1.bcr-2017-219270.3","unstructured":"Aronson JK , ed. Meyler\u2019s side effects of cardiovascular drugs. Amsterdam: Elsevier. 2009."},{"key":"2025042705582768000_2017.apr26_1.bcr-2017-219270.4","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0196-0644(94)70168-7","article-title":"Propafenone overdose","volume":"24","author":"Kerns","year":"1994","journal-title":"Ann Emerg Med"},{"key":"2025042705582768000_2017.apr26_1.bcr-2017-219270.5","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1139\/cjpp-2015-0509","article-title":"Assessment of 25 CYP2D6 alleles found in the Chinese population on propafenone metabolism in vitro","volume":"94","author":"Su","year":"2016","journal-title":"Can J Physiol Pharmacol"},{"key":"2025042705582768000_2017.apr26_1.bcr-2017-219270.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200503173521119"},{"key":"2025042705582768000_2017.apr26_1.bcr-2017-219270.7","doi-asserted-by":"publisher","DOI":"10.2165\/11318030-000000000-00000"},{"key":"2025042705582768000_2017.apr26_1.bcr-2017-219270.8","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1007\/BF01733250","article-title":"Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol, propafenone, diltiazem, and sparteine","volume":"65","author":"Wagner","year":"1987","journal-title":"Klin Wochenschr"},{"key":"2025042705582768000_2017.apr26_1.bcr-2017-219270.9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/978-1-4939-3252-8_2","article-title":"Quantitation of flecainide, mexiletine, Propafenone, and amiodarone in serum or plasma using liquid Chromatography-Tandem mass spectrometry (LC-MS\/MS)","volume":"1383","author":"Slawson","year":"2016","journal-title":"Methods Mol Biol"},{"key":"2025042705582768000_2017.apr26_1.bcr-2017-219270.10","first-page":"101","article-title":"Benefit and concern about the \"pill-in-the-pocket\"","volume":"61","author":"Mansourati","year":"2013","journal-title":"J Med Liban"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2017-219270","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T12:58:42Z","timestamp":1745758722000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2017-219270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,26]]},"references-count":10,"alternative-id":["10.1136\/bcr-2017-219270"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2017-219270","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,26]]}}}